Literature DB >> 29108824

Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate.

Gabriella Moroni1, Mariele Gatto2, Francesca Raffiotta1, Valentina Binda1, Eleni Frangou3, Liz Lightstone4, Dimitrios T Boumpas5.   

Abstract

Lupus nephritis (LN) treatment requires an initial intensive period of therapy followed by a long-term maintenance treatment in order to stabilize disease control and eventually reach renal remission. In this section, Authors discuss the feasibility of safely lowering and even suspending maintenance therapy in LN patients having entered remission, highlighting hurdles in predicting the depth and durability of disease quiescence together with the need for minimizing potentially toxic therapies. Even though no firm conclusions can still be drawn, the treating physician has to find the wise balance between disease control and treatment-related drawbacks by following patients closely and recognizing as early as possible the ones who are likely to reach a deep and durable renal remission; there is consensus that is these are the only patients in whom a potential safe complete withdrawal can be foreseen so far.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Immunosuppression; Lupus nephritis; Organ damage; Remission

Mesh:

Substances:

Year:  2017        PMID: 29108824     DOI: 10.1016/j.autrev.2017.11.003

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  4 in total

1.  Glucocorticoid discontinuation in pediatric-onset systemic lupus erythematosus: a single-center experience.

Authors:  Kentaro Nishi; Masao Ogura; Sho Ishiwa; Toru Kanamori; Mika Okutsu; Shunsuke Yokota; Taishi Nada; Mai Sato; Koichi Kamei; Kenji Ishikura; Shuichi Ito
Journal:  Pediatr Nephrol       Date:  2022-01-26       Impact factor: 3.651

Review 2.  Lupus nephritis: challenges and progress.

Authors:  Anne Davidson; Cynthia Aranow; Meggan Mackay
Journal:  Curr Opin Rheumatol       Date:  2019-11       Impact factor: 5.006

3.  Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience.

Authors:  Chiara Tani; Elena Elefante; Viola Signorini; Dina Zucchi; Valentina Lorenzoni; Linda Carli; Chiara Stagnaro; Francesco Ferro; Marta Mosca
Journal:  RMD Open       Date:  2019-06-11

4.  Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial.

Authors:  Noemie Jourde-Chiche; Nathalie Costedoat-Chalumeau; Karine Baumstarck; Anderson Loundou; Laurence Bouillet; Stéphane Burtey; Valérie Caudwell; Laurent Chiche; Lionel Couzi; Laurent Daniel; Christophe Deligny; Bertrand Dussol; Stanislas Faguer; Pierre Gobert; Guillaume Gondran; Antoine Huart; Aurélie Hummel; Emilie Kalbacher; Adexandre Karras; Marc Lambert; Véronique Le Guern; Ludivine Lebourg; Sandrine Loubière; Hélène Maillard-Lefebvre; François Maurier; Micheline Pha; Viviane Queyrel; Philippe Remy; Françoise Sarrot-Reynauld; David Verhelst; Eric Hachulla; Zahir Amoura; Eric Daugas
Journal:  Ann Rheum Dis       Date:  2022-06-20       Impact factor: 27.973

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.